Trillium Renewable Chemicals, a bio-based chemical manufacturer, announced that it has raised a US$13 million Series B financing round for the world’s first demonstration plant for bio-based acrylonitrile.

Trillium’s major milestones in bio-based acrylonitrile.

The financing was led by HS Hyosung Advanced Materials with participation from Capricorn Partners. This funding builds on the company’s previous $10.6 million Series A financing round and non-dilutive $2.5 million award from the U.S. Department of Energy.

Following a successful multi-year pilot program validating its glycerol-to-acrylonitrile technology, Trillium selected INEOS Nitriles’ Green Lake facility to host the world’s first demonstration plant for the manufacture of 100% bio-based acrylonitrile.

Construction of this Project Falcon is complete, marking the first industrial-scale deployment of Trillium’s technology. Commissioning is scheduled for second quarter 2026 with product shipments to follow later this year.

The capital raised funds 1) design and construction of Falcon (completed), 2) Falcon operation, 3) continued pilot-scale innovation, and 4) advanced stage engineering design of the first commercial plant.

Following Falcon’s commissioning, Trillium will advance engineering and development of its first commercial-scale manufacturing plant. The company is engaging strategic partners and customers now in preparation for commercial deployment.

More on acrylonitrile

Global acrylonitrile production exceeds 6 million metric tons annually and is derived almost entirely from fossil feedstocks. Trillium’s process enables a drop-in, plant-based alternative without changes to downstream supply chains.

Acrylonitrile is used to make a diverse range of consumer and industrial goods including carbon fiber, plastic, textiles, flocculant, synthetic rubber, and other valuable materials. These derivatives feed into high-value markets such as lightweight composites for aerospace and automotive, performance textiles, and specialty polymer applications.